A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer

BACKGROUND: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target of rapamycin inhibitor) might work synergistically. METHODS: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was perf...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Desar, I M E, Timmer-Bonte, J N H, Burger, D M, van der Graaf, W T A, van Herpen, C M L
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2994217/
https://ncbi.nlm.nih.gov/pubmed/21045832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605777
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados